Patrys Ltd has released a press release.
PAT-DX1 Engineering Run Successfully Completed
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Patrys
- New Mechanism By Which PAT-DX1 May Reduce Cancer Metastasis
- CBCF funding to support deoxymab brain cancer development
- Appendix 4C - Quarterly - 31 March 2022
- Application for quotation of securities - PAB
- Stable Cell Line for Production of PAT-DX3 Established
Later from Patrys
- Appendix 4C - Quarterly - 30 June 2022
- PAT-DX1/Radiation Combination Improves Brain Cancer Survival
- New Research Grant For Deoxymabs in Metastatic Breast Cancer
- PAT-DX1 From Engineering Run Meets all Specification Tests
- Appendix 4E and 2022 Annual Report
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys